Publications by Dr Michael Grayling - ePrints

Browsing publications by Dr Michael Grayling.

Newcastle Authors	Title	Year
Andrew Bryant Dr Michael Grayling Professor Dawn Craig Professor Luke Vale	Residual Disease after Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 2: Network Meta-analysis Incorporating Expert Elicitation to Adjust for Publication Bias	2023
Andrew Bryant Eugenie Johnson Dr Michael Grayling Shaun Hiu Dr Ahmed Elattar et al.	Residual Disease Threshold After Primary Surgical Treatment for Advanced Epithelial Ovarian Cancer, Part 1: A Systematic Review and Network Meta-Analysis	2023
Samuel Sarkodie Professor James Wason Dr Michael Grayling	A hybrid approach to comparing parallel-group and stepped-wedge cluster-randomized trials with a continuous primary outcome when there is uncertainty in the intra-cluster correlation	2022
Luke Ouma Dr Michael Grayling Professor James Wason Dr Haiyan Zheng	Bayesian modelling strategies for borrowing of information in randomised basket trials	2022
Dr Michael Grayling Professor Rakesh Heer Professor James Wason	Improving power in PSA response analyses of metastatic castration-resistant prostate cancer trials	2022
Dr Michael Grayling	Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials	2022
Andrew Bryant Dr Michael Grayling Shaun Hiu Eugenie Johnson Professor Luke Vale et al.	Residual disease after primary surgery for advanced epithelial ovarian cancer: expert elicitation exercise to explore opinions about potential impact of publication bias in a planned systematic review and meta-analysis	2022
Dr Faye Williamson Dr Michael Grayling Professor James Wason	Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information	2022
Dr Michele Castelli Dr Michael Grayling	The prevalence and social determinants of multimorbidity in South Africa	2022
Aritra Mukherjee Professor James Wason Dr Michael Grayling	When is a two-stage single-arm trial efficient? An evaluation of the impact of outcome delay	2022